|
gptkbp:instanceOf
|
gptkb:antibiotic
glycopeptide antibiotic
|
|
gptkbp:administeredBy
|
intramuscular injection
intravenous injection
|
|
gptkbp:ATCCode
|
J01XA02
|
|
gptkbp:CASNumber
|
61036-62-2
|
|
gptkbp:discoveredBy
|
Jean-Marie Tulkens
|
|
gptkbp:discoveredIn
|
1980s
|
|
gptkbp:eliminationHalfLife
|
70-100 hours
|
|
gptkbp:hasMolecularFormula
|
C88H97Cl2N9O33
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
teicoplanin
|
|
gptkbp:indication
|
gptkb:MRSA_infections
septicemia
endocarditis
osteomyelitis
skin and soft tissue infections
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:Sanofi
|
|
gptkbp:mechanismOfAction
|
inhibits bacterial cell wall synthesis
|
|
gptkbp:notEffectiveAgainst
|
Gram-negative bacteria
|
|
gptkbp:pregnancyCategory
|
B1 (Australia)
|
|
gptkbp:producedBy
|
Actinoplanes teichomyceticus
|
|
gptkbp:relatedTo
|
vancomycin
|
|
gptkbp:routeOfAdministration
|
IV
IM
|
|
gptkbp:sideEffect
|
fever
rash
nephrotoxicity
ototoxicity
|
|
gptkbp:spectrumOfActivity
|
Gram-positive bacteria
|
|
gptkbp:usedFor
|
treatment of Gram-positive bacterial infections
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
included
|
|
gptkbp:bfsParent
|
gptkb:Glycopeptides
|
|
gptkbp:bfsLayer
|
5
|